RecruitingPhase 3NCT06515184

Coenzyme Q10 for Gulf War Illness: A Replication Study


Sponsor

University of California, San Diego

Enrollment

192 participants

Start Date

Sep 13, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to assess whether a high quality preparation of ubiquinone (coenzyme Q10) benefits symptoms, function, and quality of life in veterans with Gulf War illness.


Eligibility

Min Age: 50 Years

Inclusion Criteria5

  • Does not have a disqualifying condition.
  • Able to travel to a local Quest facility for study blood draws.
  • Adequate internet access to allow ZoomPro visit participation and remote survey completion.
  • Health prior to the Gulf War rated as "very good" or "excellent" (to exclude persons who may have had other health conditions with different mechanisms as the cause of their symptoms).
  • Willing to defer initiation of discretionary treatments or supplements during the expected course of study participation.

Exclusion Criteria4

  • Participating in another clinical trial.
  • Still-evolving adverse effects following another medication or health condition, such as covid or fluoroquinolone use.
  • On Coumadin/ warfarin.
  • Unable to participate for the required duration of the study.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPharmaNord Bio-Quinone Active CoQ10 Gold 100mg

Each participant receives one softgel three times a day. Arm 1 receives one 100mg softgel and two placebo softgels per day. Because of the presence of the IND, the dropdown menu does not allow us to choose dietary supplement. The option "drug" was chosen as the closest permissible option.

DRUGPharmaNord Placebo

Each participant receives one softgel three times a day. Arm 3 receives three placebo softgels per day. Supplement is taken orally in divided doses, with the last softgel not close to bedtime. Because of the presence of the IND, the dropdown menu does not allow us to choose dietary supplement. The option "drug" was chosen as the closest permissible option.

DRUGPharmaNord Bio-Quinone Active CoQ10 Gold 100mg

Each participant receives one softgel three times a day. Arm 2 receives three 100mg softgels per day. Supplement is taken orally in divided doses, with the last softgel not close to bedtime. Because of the presence of the IND, the dropdown menu does not allow us to choose dietary supplement. The option "drug" was chosen as the closest permissible option.


Locations(1)

UC San Diego

La Jolla, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06515184


Related Trials